Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT02422745

COcoa Supplement and Multivitamin Outcomes Study

Conditions: Cardiovascular Disease, Cancer

Sex: All
Ages: 60 Years – N/A
Healthy volunteers: Yes
Phase: PHASE4
Enrollment: 21442
Sponsor: Brigham and Women's Hospital

Location: Brigham and Women's Hospital Boston Massachusetts

Summary

The purpose of this study is to determine whether taking daily, dietary supplements of cocoa extract (containing cocoa flavanols and theobromine from the cocoa bean) and/or a standard multivitamin reduces the risk of developing cardiovascular disease (including heart attack, stroke, coronary revascularization, unstable angina or acute coronary syndrome (ACS) requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty, and cardiovascular mortality) and cancer.

Eligibility Criteria

Inclusion Criteria: 1. Women ≥ 65 years of age participating in the Women's Health Initiative (WHI) Extension Study. 2. Men ≥ 60 years of age and women age ≥ 65 years of age who were contacted for but not randomized into the VITAL trial. 3. Other women ≥ 65 years of age and men aged ≥ 60 years of age who responded to targeted mass mailings and volunteers who learned about the trial through the media or through ResearchMatch.org, an electronic recruitment website. 4. Willing to participate, as evidenced by providing informed consent and completing all required baseline forms. Exclusion Criteria: 1. History of myocardial infarction or stroke. 2. Diagnosed with invasive cancer other than non-melanoma skin cancer in the last 2 years prior to enrollment. 3. Any serious illness that would preclude participation and/or completion of the trial, including the diagnosis of kidney failure and current dialysis treatment. 4. Taking cocoa extract or multivitamin supplements and not willing to forego use during the trial. 5. Taking total supplemental vitamin D \> 1,000 IU/day and not willing to forego use during the trial. 6. Taking total supplemental calcium \> 1,200 mg/day and not willing to forego use during the trial. 7. Extreme sensitivity to caffeine. 8. Consume \< 75% of the expected number of both types of supplements during the run-in phase. 9. Unable to communicate in English due to language barrier or mental incapacity.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02422745). StuddyBuddy aggregates publicly available trial information.